Daily Stock Analysis, AMAG, AMAG Pharmaceuticals Inc, priceseries

AMAG Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
21.25
Close
21.75
High
21.85
Low
21.20
Previous Close
21.12
Daily Price Gain
0.62
YTD High
25.62
YTD High Date
Jun 6, 2018
YTD Low
11.95
YTD Low Date
Feb 9, 2018
YTD Price Change
7.15
YTD Gain
48.97%
52 Week High
25.62
52 Week High Date
Jun 6, 2018
52 Week Low
11.93
52 Week Low Date
Nov 2, 2017
52 Week Price Change
3.40
52 Week Gain
18.53%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 6. 2017
18.20
Sep 18. 2017
19.39
8 Trading Days
6.54%
Link
LONG
Feb 13. 2018
13.70
Mar 13. 2018
19.78
19 Trading Days
44.37%
Link
LONG
May 7. 2018
20.70
May 23. 2018
23.04
12 Trading Days
11.28%
Link
Company Information
Stock Symbol
AMAG
Exchange
NasdaqGS
Company URL
http://www.amagpharma.com
Company Phone
6174983300
CEO
William K. Heiden
Headquarters
Massachusetts
Business Address
1100 WINTER STREET, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0000792977
About

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.